JP2023551203A5 - - Google Patents

Info

Publication number
JP2023551203A5
JP2023551203A5 JP2023530743A JP2023530743A JP2023551203A5 JP 2023551203 A5 JP2023551203 A5 JP 2023551203A5 JP 2023530743 A JP2023530743 A JP 2023530743A JP 2023530743 A JP2023530743 A JP 2023530743A JP 2023551203 A5 JP2023551203 A5 JP 2023551203A5
Authority
JP
Japan
Prior art keywords
substituted
alkyl
aryl
conjugate
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023530743A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023551203A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/060193 external-priority patent/WO2022109335A1/en
Publication of JP2023551203A publication Critical patent/JP2023551203A/ja
Publication of JP2023551203A5 publication Critical patent/JP2023551203A5/ja
Pending legal-status Critical Current

Links

JP2023530743A 2020-11-20 2021-11-19 抗体-薬物コンジュゲートのためのグリコシド二重切断リンカー Pending JP2023551203A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063116632P 2020-11-20 2020-11-20
US63/116,632 2020-11-20
US202163139685P 2021-01-20 2021-01-20
US63/139,685 2021-01-20
PCT/US2021/060193 WO2022109335A1 (en) 2020-11-20 2021-11-19 Glycoside dual-cleavage linkers for antibody-drug conjugates

Publications (2)

Publication Number Publication Date
JP2023551203A JP2023551203A (ja) 2023-12-07
JP2023551203A5 true JP2023551203A5 (cg-RX-API-DMAC10.html) 2024-11-26

Family

ID=81708155

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023530743A Pending JP2023551203A (ja) 2020-11-20 2021-11-19 抗体-薬物コンジュゲートのためのグリコシド二重切断リンカー

Country Status (8)

Country Link
US (2) US12187810B2 (cg-RX-API-DMAC10.html)
EP (1) EP4247829A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023551203A (cg-RX-API-DMAC10.html)
KR (1) KR20230122008A (cg-RX-API-DMAC10.html)
AU (1) AU2021382033A1 (cg-RX-API-DMAC10.html)
CA (1) CA3201005A1 (cg-RX-API-DMAC10.html)
MX (1) MX2023005979A (cg-RX-API-DMAC10.html)
WO (1) WO2022109335A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023396827A1 (en) 2022-12-13 2025-06-19 Crinetics Pharmaceuticals, Inc. Somatostatin subtype-2 receptor (sst2r) targeted therapeutics and uses thereof

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
AU658396B2 (en) 1991-03-06 1995-04-13 Merck Patent Gesellschaft Mit Beschrankter Haftung Humanized and chimeric monoclonal antibodies
TW197439B (cg-RX-API-DMAC10.html) 1991-04-04 1993-01-01 Ueno Pharmaceutics Applic Res Co Ltd
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US5283253A (en) 1991-09-23 1994-02-01 Florida State University Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993010076A1 (en) 1991-11-22 1993-05-27 The University Of Mississippi Synthesis and optical resolution of the taxol side chain and related compounds
GB9125979D0 (en) 1991-12-06 1992-02-05 Wellcome Found Antibody
US5863537A (en) 1992-02-19 1999-01-26 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US5200534A (en) 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
AU4242993A (en) 1992-05-21 1993-12-13 Penn State Research Foundation, The Cultured (taxus) tissues as a source of taxol, related taxanes and other novel anti-tumor/anti-viral compounds
US5274137A (en) 1992-06-23 1993-12-28 Nicolaou K C Intermediates for preparation of taxols
US5294637A (en) 1992-07-01 1994-03-15 Bristol-Myers Squibb Company Fluoro taxols
US5202448A (en) 1992-08-14 1993-04-13 Napro Biotherapeutics, Inc. Processes of converting taxanes into baccatin III
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CA2100808A1 (en) 1992-10-01 1994-04-02 Vittorio Farina Deoxy paclitaxels
FR2696462B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
FR2696458B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
FR2696461B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveaux dérivés d'analogues du taxol, leur préparation et les compositions qui les contiennent.
FR2696463B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
FR2696464B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveau procédé d'estérification de la baccatine III et de la désacétyl-10 baccatine III.
US5279949A (en) 1992-12-07 1994-01-18 Board Of Trustees Operating Michigan State University Process for the isolation and purification of taxol and taxanes from Taxus spp
US5824701A (en) 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US5705154A (en) 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
EP0831100B1 (en) 1995-04-21 2000-10-11 Teikoku Hormone Mfg. Co., Ltd. Novel peptide derivatives
WO1998008833A1 (en) 1996-08-26 1998-03-05 Bristol-Myers Squibb Company Sulfenamide taxane derivatives
AU739028B2 (en) 1996-09-27 2001-10-04 Bristol-Myers Squibb Company Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
WO1998022451A1 (en) 1996-11-19 1998-05-28 Daiichi Pharmaceutical Co., Ltd. Taxol derivatives
US5977386A (en) 1996-12-24 1999-11-02 Bristol-Myers Squibb Company 6-thio-substituted paclitaxels
DE69829891T2 (de) 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF Antikörper
CN104231078A (zh) 1997-04-07 2014-12-24 基因技术股份有限公司 抗-血管内皮生长因子的抗体
IL133585A0 (en) 1997-06-20 2001-04-30 Baker Norton Pharma Soluble prodrugs of paclitaxel
US7288665B1 (en) 1997-08-18 2007-10-30 Florida State University Process for selective derivatization of taxanes
JPH1192468A (ja) 1997-09-17 1999-04-06 Yakult Honsha Co Ltd 新規なタキサン誘導体
WO1999018113A1 (fr) 1997-10-08 1999-04-15 Bio Research Corporation Of Yokohama Derives taxoides et leur procede de production
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
US6570040B2 (en) 2000-03-16 2003-05-27 The Regents Of The University Of California Chemoselective ligation
AU2003264009A1 (en) 2002-08-15 2004-03-03 Epitomics, Inc. Humanized rabbit antibodies
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
CN100415765C (zh) 2003-08-07 2008-09-03 宜康公司 兔单克隆抗体的人源化方法
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
WO2009120611A2 (en) 2008-03-27 2009-10-01 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
US9310374B2 (en) * 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
CN115504924A (zh) 2013-11-27 2022-12-23 雷德伍德生物科技股份有限公司 肼基-吡咯并化合物及用于生成缀合物的方法
US10973920B2 (en) 2014-06-30 2021-04-13 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
RU2017123942A (ru) * 2014-12-09 2019-01-11 Эббви Инк. Ингибирующие bcl-xl соединения, обладающие низкой клеточной проницаемостью, и коньюгаты антитело-лекарственное средство, включающие их
KR20180021705A (ko) * 2015-06-30 2018-03-05 시애틀 지네틱스, 인크. 항-ntb-a 항체 및 관련 조성물 및 방법
CN111065416B (zh) * 2017-06-21 2024-09-13 芬兰吉利科斯有限公司 亲水性接头及其共轭物
CN109275190B (zh) * 2017-07-17 2021-10-26 华为技术有限公司 一种通信方法及装置
MX2020006010A (es) * 2017-12-11 2020-10-16 Triphase Res And Development Iii Corp Conjugados de anticuerpo anti-cd22-maitansina, combinaciones y metodos de uso de los mismos.
WO2020096775A1 (en) * 2018-11-09 2020-05-14 R.P. Scherer Technologies, Llc Sulfatase-cleavable linkers for antibody-drug conjugates
WO2020154437A1 (en) * 2019-01-23 2020-07-30 R.P. Scherer Technologies, Llc Glycoside-containing peptide linkers for antibody-drug conjugates
EP4294453B1 (en) 2021-02-16 2026-07-29 Glykos Finland Oy Linker-payloads and conjugates thereof

Similar Documents

Publication Publication Date Title
JP2022518743A5 (cg-RX-API-DMAC10.html)
JP7403507B2 (ja) 薬物としてアマトキシンの誘導体を有する抗体薬物コンジュゲート
AU2022259796B2 (en) Antibody drug conjugates comprising STING agonists
JP6908656B2 (ja) 薬物結合体のためのスルホンアミド含有連結系
JP2024510927A5 (cg-RX-API-DMAC10.html)
CN113874046B (zh) 用于抗体-药物缀合物的含有糖苷的肽接头
JP2022530524A5 (cg-RX-API-DMAC10.html)
CN114430738A (zh) 可编程的聚合药物
CA3067311A1 (en) Cd38 antibody drug conjugate
JP2014513717A5 (cg-RX-API-DMAC10.html)
CA2923862C (en) Bifunctional cytotoxic agents containing the cti pharmacophore
AR051565A1 (es) DERIVADOS DE IMIDAZO[1, 2 - A]PIRIDINA; MÉTODOS PARA SU PREPARACIoN; COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SU USO EN LA ELABORACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES E INFECCIONES POR VIH MEDIADAS POR CXCR4.
JP2024529466A5 (cg-RX-API-DMAC10.html)
TW202132332A (zh) IL—2Rβγc結合化合物
RU2009121626A (ru) Соединения агонисты рецептора глюкагоноподобного белка-1 (glp-1r)
RU2014123021A (ru) Молекула, содержащая spr0096 и spr2021
RU2018120696A (ru) Конъюгаты анти-cd22 антитело-майтансин и способы их применения
TW202027786A (zh) 包含抗原肽- 佐劑核苷酸結合物之免疫誘導劑及包含其之醫藥組成物
WO2024005460A1 (ko) 자가-희생기를 포함하는 화합물 및 이를 포함하는 리간드-약물 접합체
WO2024160176A1 (zh) 一类连接子药物及其抗体-药物偶联物的制备方法和应用
WO2024235130A9 (zh) 多环化合物及其制备方法和用途
WO2024235133A9 (zh) 多环类药物偶联物及其制备方法和用途
AR121894A1 (es) Conjugados de anticuerpos de fármacos
JP2025516569A5 (cg-RX-API-DMAC10.html)
EP4463149A2 (en) Compound comprising raltitrexed or 5-mthf linked to a therapeutic agent, composition, and method of use